|
1）Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362: 2380-8
|
|
|
|
2）Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor （WJTOG3405）: an open label, randomised phase 3 trial. Lancet Oncol. 2010; 11: 121-8
|
|
|
|
|
|
3）Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer （OPTIMAL, CTONG-0802）: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011: 12: 735-42
|
|
|
|
|
|
4）Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer （EURTAC）: a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13: 239-46
|
|
|
|
|
|
5）Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013; 31: 3327-34
|
|
|
|
|
|
6）Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations （LUX-Lung 6）: an open-label, randomised phase 3 trial. Lancet Oncol. 2014; 15: 213-22
|
|
|
|
|
|
7）Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma （LUX-Lung 3 and LUX-Lung 6）: analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015; 16: 141-51
|
|
|
|
|
|
8）Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005; 352: 786-92
|
|
|
|
|
|
9）Jänne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015; 372: 1689-99
|
|
|
|
|
|
10）Sequist LV, Soria JC, Goldman JW, et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2015: 372: 1700-9
|
|
|
|
|
|
11）Inoue A, Kobayashi K, Maemondo M, et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations （NEJ002）. Ann Oncol. 2013; 24: 54-9
|
|
|
|
|
|
12）Simon R, Norton L. The Norton-Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens. Nat Clin Pract Oncol. 2006; 3: 406-7
|
|
|
|
|
|
13）Takezawa K, Okamoto I, Tanizaki J, et al. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor. Mol Cancer Ther. 2010; 9: 1647-56
|
|
|
|
|
|
14）Sugawara S, Oizumi S, Minato K, et al. Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902. Ann Oncol. 2015; 26: 888-94
|
|
|
|
|
|
15）Naumov GN, Nilsson MB, Cascone T, et al. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor （EGFR） blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res. 2009; 15: 3484-94
|
|
|
|
|
|
16）Seto T, Kato T, Nishio M, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations （JO25567）: an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014; 15: 1236-44
|
|
|
|
|
|
17）Solit DB, She Y, Lobo J, et al. Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel. Clin Cancer Res. 2005; 11: 1983-9
|
|
|
|
|
|
18）Yamaguchi H, Hsu JL, Chen CT, et al. Caspase-independent cell death is involved in the nega-tive effect of EGF receptor inhibitors on cisplatin in non-small cell lung cancer cells. Clin Cancer Res. 2013; 19: 845-54
|
|
|
|
|
|
19）Mok TS, Nakagawa W, Kim S, et al. Gefitinib/chemotherapy versus chemotherapy in epidermal growth factor receptor （EGFR） mutation-positive non-small cell lung cancer after progression on first-line gefitinib: the phase III, randomized IMPRESS study. ESMO 2014 Congress
|
|
|
|
|
|
20）Schuler MH, Yang CH, Park K,et al. Continuation of afatinib beyond progression: results of a randomized, open-label, phase III trial of afatinib plus paclitaxel （P） versus investigator’s choice chemotherapy （CT） in patients （pts） with metastatic non-small cell lung cancer （NSCLC） progressed on erlotinib/gefitinib （E/G） and afatinib—LUX-Lung 5 （LL5）. J Clin Oncol. 2014. 32: 5s（suppl; abstr 8019）
|
|
|
|
|
|
21）Wu YL, Lee JS, Thongprasert S, et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer （FASTACT-2）: a randomised, double-blind trial. Lancet Oncol. 2013; 14: 777-86
|
|
|
|
|
|
22）Kanda S, Ohe Y, Horinouchi H, et al. Phase II study of gefitinib and inserted cisplatin plus docetaxel as a first-line treatment for advanced non-small cell lung cancer haboring an epidermal growth factor receptor activating mutation. J Clin Oncol. 2013; 31（suppl; abstr 8064）
|
|
|
|
|